Participant flow

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenously on Days 1, 4, 8, 11.

   id

   FG000

   title

   Vorinostat + Bortezomib

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Trial terminated due to slow accrual, only 1 patient registered.

recruitment Details

Recruitment Period: 02/17/09 through 04/26/10. All participants recruited at UT MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice